Skip to main content
Premium Trial:

Request an Annual Quote

Novigenix-Led Consortium Awarded Up to €1M to Develop Predictive Immune Checkpoint Inhibitor Test

NEW YORK — A research consortium led by Novigenix has received a Eurostars grant worth up to €1 million ($1.2 million) to develop a blood-based test to predict cancer patient responses to immune checkpoint inhibitors (ICIs), the Swiss molecular diagnostics firm said on Tuesday.

According to Novigenix, the consortium — which includes PamGene International and Radboud University — has already generated data predicting metastatic urothelial cancer patients' responses to anti-PD-1 checkpoint inhibitors.

The group will build off this work using use mRNA and kinase activity profiling to identify multi-omic predictive signatures for ICI response with Novigenix contributing its expertise in immuno-transcriptomics and artificial intelligence, PamGene providing kinome technology, and Radboud University researchers leading a clinical network for the prospective collection of biological specimens and data interpretation.

In January, Novigenix and collaborators were awarded up to €1 million from Eurostars, which is funded by European governments and the European Union, to develop a blood-based multi-omics colorectal cancer assay.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.